Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 16/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018602 | 0.91 | GHSR (0.57) | GHSRPPARACTSSPPARG | |
| SCHEMBL17018603 | 0.89 | GHSR (0.64) | GHSRPPARACTSSPPARG | |
| SCHEMBL17018565 | 0.89 | GHSR (0.58) | GHSRPPARACTSSPPARG | |
| SCHEMBL17018451 | 0.79 | PPARA (0.54) | GHSRPPARACTSSPPARGMEN1 | |
| SCHEMBL17018575 | 0.79 | MAPK1 (0.43) | CTSSMEN1KMT2ANPSR1 | |
| SCHEMBL13184604 | 0.79 | PPARA (0.65) | PPARACTSSPPARG | |
| SCHEMBL19312176 | 0.79 | PPARA (0.65) | PPARACTSSPPARG | |
| SCHEMBL17018566 | 0.78 | GHSR (0.58) | GHSRPPARA | |
| SCHEMBL23390363 | 0.76 | PPARA (0.67) | PPARACTSSPPARG | |
| SCHEMBL506388 | 0.76 | PPARA (0.67) | PPARACTSSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | GHSR 1729/4885PPARA 857/4885CTSS 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.